Grant & Award Recipients

Below is a list of grant and award recipients. You may narrow the list down by using the filters below. The list can be sorted by year, last name, and institution. The institution listed reflects the sponsoring institution at the time of grant or award.

View All Recipients

Past Recipients Year First Name Last Name Degree Institution Title
2017 Nabil Adra MD Indiana University Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT).
2017 Saud AlDubayan MD Dana-Farber Cancer Institute Enrichment of germline DNA-repair gene mutations in patients with colorectal cancer.
2017 Rita Assi MD The University of Texas M.D. Anderson Cancer Center Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL).
2017 Min Sun Bae MD, PhD Memorial Sloan Kettering Cancer Center Survival outcomes of screening with breast MRI in high-risk women.
2017 Luis Baez-Vallecillo MD The University of Texas M.D. Anderson Cancer Center Whole exome sequencing of metaplastic breast cancer (MpBC): Mutation status impacts survival.
2017 Martin D. Berger MD University of Southern California Genetic variations within the vitamin C transporter genes predict outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
2017 Maria Carlo MD Memorial Sloan Kettering Cancer Center Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B).
2017 Jung-Woo Chae PhD National University of Singapore, Singapore Mitochondrial DNA content in peripheral blood as a biomarker for cancer-related fatigue in early-stage breast cancer patients: A prospective cohort study.
2017 Rajshekhar Chakraborty MD Mayo Clinic Prognostic impact of kinetics of circulating plasma cells before and after induction therapy in newly diagnosed multiple myeloma patients undergoing early transplantation.
2017 Kamal Chamoun MD The University of Texas M.D. Anderson Cancer Center Immune-related gene expression deficit of leukemia stem cells (LSC) in AML.
2017 Aadel Chaudhuri MD, PhD Stanford University Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies.
2017 Runzhe Chen MD, MS Southeast University, China Synergism of gambogenic acid with bortezomib induce apoptosis of multiple myeloma.
2017 Maxime Chenard-Poirier MD The Royal Marsden Hospital, United Kingdom Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.
2017 Michael Cheng MD Memorial Sloan Kettering Cancer Center Potentially actionable somatic and germline alterations in advanced prostate cancer identified by next-generation sequencing (NGS) of tissue and cell free DNA (cfDNA).
2017 Yin Ting Cheung PhD St. Jude Children's Research Hospital Biomarkers of brain injury and neurologic outcomes in children treated with chemotherapy for acute lymphoblastic leukemia (ALL).
2017 Vincenza Conteduca MD, PhD The Institute of Cancer Research, United Kingdom Androgen receptor (AR) status in plasma DNA associates with worse outcome on enzalutamide (enza) or abiraterone (abi) for castration resistant prostate cancer (CRPC).
2017 Gwen Dackus MD The Netherlands Cancer Institute Long-term outcome of breast cancer patients diagnosed ≤40 years according to breast cancer subtype in the absence of adjuvant systemic therapy: The PARADIGM initiative.
2017 Ibiayi Dagogo-Jack MD Massachusetts General Hospital Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK+) non-small cell lung cancer (NSCLC).
2017 Christine Dahl MD, PhD The Hospital for Sick Children, Canada Neurocognitive outcome in children with sensorineural hearing loss after treatment of malignant embryonal brain tumors.
2017 Katja De Paepe MD University Hospitals Leuven, Belgium Whole body diffusion-weighted MRI can predict treatment outcome after one cycle of immunochemotherapy in aggressive non-Hodgkin lymphoma.
2017 Joseph Del Paggio MD University of Toronto, Canada Delivery of meaningful cancer care: Evaluating benefit and cost of cancer therapies using ASCO and ESMO frameworks.
2017 Lisa Derosa MD, PhD Institut Gustave Roussy, France Antibiotics prescription decreases progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors.
2017 Nicholas DeVito MD Duke University Paracrine wnt-β-catenin signaling inhibition as a strategy to enhance the efficacy of anti-PD-1 antibody (Ab) therapy in a transgenic model of melanoma.
2017 Clarissa Diniz Johns Hopkins University Comparison of biochemical recurrence free survival after radical prostatectomy triggered by grade reclassification on active surveillance, and men newly diagnosed with similar grade disease.
2017 Joshua Drago MD Massachusetts General Hospital FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer.
2017 Temidayo Fadelu MD Dana-Farber Cancer Institute Nut consumption and survival in stage III colon cancer patients: Results from CALGB 89803 (Alliance).
2017 Farhad Fakhrejahani MD National Cancer Institute, National Institutes of Health Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
2017 Zachary Frosch MD Brigham and Women's Hospital What does the general population think about chemotherapy shortages?
2017 Ketan Ghate MD Queen's University, Canada Resource utilization in patients with head and neck cancer: Analysis of CCTG HN6 (NCT00820248).
2017 James Godfrey MD The University of Chicago Autologous (auto) versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapy failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.
2017 Chelain Goodman MD Northwestern University Circulating tumor cell status and benefit of radiotherapy in stage I breast cancer.
2017 Donna Graham BSc, MB, MRCPUK Queen's University, Ireland Assessment of conditional survival probability in resected esophageal adenocarcinoma.
2017 Gillian Gresham MSc Cedars-Sinai Medical Center Assessing performance status and clinical outcomes with wearable activity monitors.
2017 Nicolas Guibert MD Dana-Farber Cancer Institute Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.
2017 Evan Hall MD, M.Phil. Stanford University Pathogenic germline mutations in emerging cancer genes: What happens after panel testing?
2017 Arielle Heeke MD Georgetown University Prevalence of homologous recombination deficiency among all tumor types.
2017 Robert Hillman MD, PhD The University of Texas M.D. Anderson Cancer Center A novel genomic rearrangement signature predicts poor survival among women with high grade serous ovarian cancer.
2017 Anna Hoppmann MD, MPH University of Alabama, Birmingham Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study.
2017 Jessica Hudson MD, MSC Washington University The role of adjuvant chemotherapy in stage IB non-small cell lung cancer: A decision, effectiveness, and cost-effectiveness analysis.
2017 Ecaterina Ileana Dumbrava MD The University of Texas M.D. Anderson Cancer Center Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors.
2017 Maya Ilowite MD Dana-Farber Cancer Institute Disparities in prognosis communication among parents of children with cancer: The impact of race and ethnicity.
2017 Anuradha Jayaram MBBS, MRCP The Royal Marsden Hospital, United Kingdom Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.
2017 Sheheryar Kabraji MD Massachusetts General Hospital AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer patients.
2017 Kai Kang PhD The Cleveland Clinic Tetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC enhances immunotherapeutic effect of anti-PD1 in vivo.
2017 Ciara Kelly MBBS Memorial Sloan Kettering Cancer Center The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST).
2017 Daniel Khalaf MD British Columbia Cancer Agency Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).
2017 Rebecca Kim BA The University of Pennsylvania Chimeric antigen receptor (CAR) T cells induce clonal expansion of endogenous non-CAR T cells in patients (pts) with advanced solid cancer.
2017 Vadim Koshkin MD The Cleveland Clinic Molecular Profiling of Small Cell Bladder Cancer (SCBC) Reveals Gene Expression Determinants of an Aggressive Phenotype.
2017 Curtis Lachowiez MD Oregon Health & Science University Implementation of a screening program for identification of unrecognized inherited marrow failure syndromes.
2017 Arjun Lakshman MD, MRCP Mayo Clinic Natural history of t(11;14) multiple myeloma (MM).